⚠️ IMPORTANT: Nothing in this article is medical advice. Retatrutide (“Reta”) is an investigational, non‑FDA‑approved drug still in Phase 3 clinical trials. Always consult a licensed physician with any health concerns.
Reviewed by: Alex M. Rivera, B.S. Molecular Biology
🔍 Introduction: The Glucagon “Signature”
Retatrutide (LY3437943, often shortened to “Reta”) is a first‑in‑class triple‑hormone‑receptor agonist. It activates three receptors in a single molecule: GLP‑1R, GIPR, and GCGR. This triple action drives exceptional weight loss — up to 24.2% after 48 weeks in Phase 2 — but also produces a specific, mechanism‑driven safety signal: a modest, dose‑dependent increase in resting heart rate that has attracted close clinical attention. The heart‑rate elevation is tied primarily to glucagon‑receptor (GCGR) activation, making Reta unique among incretin‑based therapies.
This review synthesizes the current evidence on Retatrutide’s effects on heart rate, arrhythmias, and broader cardiovascular risk markers, drawing exclusively from peer‑reviewed publications, clinical trial registries, and the latest Phase 3 disclosures.
1. The Mechanism Behind the Beat
GLP‑1 receptor agonism is known to increase heart rate by roughly 3–5 bpm. Retatrutide adds a second chronotropic driver — glucagon‑receptor activation — which signals through cAMP/PKA pathways in the sinoatrial node to raise firing rate. The net effect is a slightly higher resting heart‑rate elevation than that seen with single or dual agonists.
Source: Retatrutide stimulates GCGR, GIPR, and GLP‑1R, increasing cAMP and PKA signaling. This excites beating rate via GCGR in the sinus node, partly through HCN channels.
2. Phase 2 Quantitative Data
The landmark Phase 2 obesity trial (Jastreboff 2023, N Engl J Med) provides the most complete dataset. By the end of the 48‑week study, the mean increase in resting heart rate from baseline was:
| Dose | Approx. Heart Rate Increase (bpm) |
| Placebo | +1 bpm |
| 1 mg | +3–4 bpm |
| 4 mg | +5–6 bpm |
| 8 mg | +6–7 bpm |
| 12 mg | +6–7 bpm |
Data adapted from: Jastreboff AM, et al. NEJM. 2023. Additional reporting from PeptidesLabUK Phase 2 safety review.
Key takeaway: The magnitude of heart‑rate increase is modest — approximately +6 bpm at the two highest doses — and appears to plateau above 8 mg.
A separate literature review in Expert Opin Investig Drugs (Ray A, 2023) reported that heart rate was increased by up to 6.7 beats/min by retatrutide, a signal that may partly offset some cardiometabolic benefits of weight loss.
3. Comparison to Other GLP-1 Drugs
| Drug | Mechanism | Heart Rate Increase (bpm) |
| Retatrutide (Reta) | GLP‑1 + GIP + glucagon | +6–7 bpm (highest doses) |
| Tirzepatide (Mounjaro/Zepbound) | GLP‑1 + GIP | +3–5 bpm |
| Semaglutide (Ozempic/Wegovy) | GLP‑1 only | +3–4 bpm |
Sources: SURMOUNT‑1 trial for tirzepatide; STEP trials for semaglutide; Retatrutide Phase 2 for Reta. This modest excess is consistent with GCGR agonism increasing energy expenditure beyond appetite suppression.
Retatrutide’s heart‑rate elevation is thus predictable, dose‑dependent, and not unexpected given its triple‑agonist design.
4. Temporal Pattern: Peaks Then Declines
One of the most reassuring findings from the Phase II trial is that dose‑dependent increases in heart rate peaked at 24 weeks and declined thereafter. Later time points (up to week 48) showed a modest attenuation, suggesting tachyphylaxis or physiological adaptation. While this is not a complete reversal, it reduces the likelihood of sustained rate‑related adverse effects during chronic dosing.
5. Arrhythmia Signal: Mild, Dose-Dependent
The 2023 Expert Opin Investig Drugs review (Ray A) noted: “Dose‑dependent increase in heart rate and incidents of mild to moderate cardiac arrhythmias raise cardiovascular safety concerns and signify that carrying out long‑term cardiovascular outcome trials (CVOTs) will be critical.”
No severe (Grade 3 or higher) arrhythmia events were reported in Phase 2. All identified arrhythmias were mild or moderate, did not lead to discontinuation in the vast majority of cases, and resolved without intervention.
Bottom line: The arrhythmia signal exists but is small and clinically manageable in the trial setting.
6. Phase 3 Data: Cardiovascular Risk Markers Improve
Phase 3 results (TRANSCEND trial, 2026) reported that participants receiving the highest dose achieved a 2.0% HbA1c reduction and 1.7–2.0 percentage point A1c reductions (depending on analysis). Body weight fell by 16.8% in the highest‑dose cohort over 40 weeks. Notably, the same trial recorded clinically meaningful improvements across multiple cardiovascular risk markers:
- Non‑HDL cholesterol – significant reduction
- Triglycerides – significant reduction
- Systolic blood pressure – significant reduction
Sources: Eli Lilly Phase 3 announcement 2026; Medscape reporting on the same data.
Thus, despite a slightly elevated resting heart rate, Retatrutide appears to improve many other CV risk factors, potentially offsetting or outweighing the chronotropic effect.
7. Ongoing Definitive Trial: TRIUMPH‑Outcomes (NCT06383390)
To resolve the net cardiovascular impact, the TRIUMPH‑Outcomes Phase 3 trial is currently recruiting. This five‑year study will determine whether retatrutide significantly lowers the incidence of serious heart‑related complications (MACE+) or prevents worsening of kidney function in patients with obesity and established atherosclerotic cardiovascular disease and/or chronic kidney disease. Until these results are available — expected around 2030 — the balance of benefits versus risks remains under active investigation.
Summary for Researchers
| Parameter | Finding |
| Peak HR elevation (12 mg) | +6–7 bpm above baseline |
| Time course | Peaks at week 24, declines modestly by week 48 |
| Arrhythmias | Mild/moderate, dose‑dependent, no severe events |
| BP & lipids | Systolic BP reduced; non‑HDL and triglycerides ↓ |
| Definitive CV trial | TRIUMPH‑Outcomes ongoing (5‑year, primary outcome MACE+) |
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone‑Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526. DOI: 10.1056/NEJMoa2301972
- Healthcare Communications Network. Triple–Hormone‑Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. June 2023
- PeptidesLabUK. Retatrutide Side Effects and Safety Profile: A 2026 UK Research Review of Phase 2 Adverse Events, Heart Rate, Hepatic and GI Signals. April 2026
- Ray A. Retatrutide: a triple incretin receptor agonist for obesity management. Expert Opin Investig Drugs. 2023;32(11):1003-1008. DOI: 10.1080/13543784.2023.2276754
- Eli Lilly. Lilly’s Triple Agonist Retatrutide Demonstrated Significant A1C and Body Weight Reductions in Phase 3 Trial for Adults with Type 2 Diabetes. News release, March 19, 2026
- TrialX. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH‑Outcomes). ClinicalTrials.gov NCT06383390
- Contractile effects of retatrutide in isolated mouse atrial preparations. PMC. 2025
- Lilly Phase 3 TRANSCEND Data. Islip Surgery. March 2026
- S. A. Doggrell. Is retatrutide… a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023
- Medscape. Triple Agonist Retatrutide Reduces A1c, Weight in T2D. March 2026
This article was written and reviewed by Alex M. Rivera, B.S. Molecular Biology, our in‑house science reviewer. Alex relies exclusively on peer‑reviewed trials and updates content routinely. No medical advice — always consult a doctor.